Article
In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.
Microbiology spectrum - 2 Jul 2024
Gracias Ségolène, El Yaalaoui Ikrame, Visseaux Benoît, Charpentier Charlotte, Descamps Diane, Martin Charlène, Lermechain Fanny, Plantier Jean-Christophe, Alessandri-Gradt Elodie
Abstract excerpt
The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic diversity. The results were compared to the reference strains of HIV-1 group M (HIV-1/M) with known tropism. Among the non-M strains, a wide range of phenotypic...
Topics
- HIV-1
- Maraviroc
- Humans
- CCR5 Receptor Antagonists
- HIV Infections
- Viral Tropism
- Inhibitory Concentration 50
- Triazoles
- Phenotype
- Microbial Sensitivity Tests
